Loading
A phase 2 trial of AZD0486 in hodgkin lymphoma and non-hodgkin lymphoma, run by AstraZeneca, now recruiting.
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL is a phase 2 interventional study registered as NCT06526793 by AstraZeneca, with 270 participants planned, started 2024-11-27 and due to reach its primary completion in 2028-04-21. Interventions recorded: Surovatamig. Conditions listed: B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AZD0486, Follicular lymphoma, AstraZeneca.
Shares AZD0486, AstraZeneca.
Shares AZD0486, AstraZeneca.
Shares AZD0486, Hodgkin lymphoma, AstraZeneca, Non-Hodgkin lymphoma (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/